Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANT195
- Development stage
- Preclinical
- Lead developer
- Cambium Oncology
- Modality
- Small Molecules
01
Overview
ANT195 is a preclinical-stage small molecule therapeutic being developed by Cambium Oncology for the treatment of Acute Myeloid Leukemia (AML). It is designed to target the VIP/VPAC axis, which comprises the Vasoactive Intestinal Peptide (VIP) and its associated G protein-coupled receptors, VPAC1 and VPAC2. This signaling axis is known to play a significant role in the tumor microenvironment, contributing to immune evasion and the proliferation of malignant cells in various hematological and solid tumors. ANT195 aims to modulate this pathway to inhibit leukemic cell growth and survival, representing a targeted approach within Cambium Oncology's core technology platform.
02
Targets
VIPR1 (Vasoactive intestinal peptide receptor 1)VIPR2 (Vasoactive intestinal polypeptide receptor 2)
Beyond the preview
Go deeper on ANT195.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANT195.